| Heading: |
Diagnosis |
| Question ID: |
1804771 |
| UIN: |
HL7718 |
| House: |
Lords |
| Date tabled: |
2025-05-20 |
| Asking Member ID: |
4970 |
| Asking Member display name: |
Lord Weir of Ballyholme
|
| Asking Member handle: |
LordWeirDUP
|
| Asking Member Twitter reference: |
@LordWeirDUP
|
| Member interest: |
false |
| Question text: |
To ask His Majesty's Government what assessment they have made of the level of investment required to extend capacity and capability for cerebrospinal fluid and blood-based biomarker testing within this Parliament. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-05 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
347 |
| Answering Member display name: |
Baroness Merron
|
| Answering Member handle: |
|
| Answering Member Twitter reference: |
Baroness Merron
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
NHS England has established a dedicated programme team to prepare the National Health Service for the potential arrival of new Alzheimer’s treatments that are approved by the Medicines and Healthcare products Regulatory Agency and determined to be clinica... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |